title: A view on dendritic cell immunotherapy in ovarian cancer: how far have we come?
abstract: Ovarian cancer is the second most important pelvic gynaecologic malignancy and nowadays still kills 80% of patients. New treatment options are mandatory. Although it has been shown that ovarian cancer is an immunogenic tumor, the possibility of developing immunotherapy has been neglected for a long time. This article focuses on the importance of the immune system in the development and progression of cancer and the possibilities and problems of dendritic cell-based immunotherapy to influence the immune system.
authors.affiliation: Department of Oncology, KU Leuven, Herestraat 49, 3000 Leuven, Belgium. ; UZ Leuven, Gynaecology and Obstetrics, Herestraat 49, 3000 Leuven, Belgium.
authors.forename: A
authors.initials: A
authors.lastname: Coosemans
authors.affiliation: Department of Oncology, KU Leuven, Herestraat 49, 3000 Leuven, Belgium. ; UZ Leuven, Gynaecology and Obstetrics, Herestraat 49, 3000 Leuven, Belgium.
authors.forename: T
authors.initials: T
authors.lastname: Baert
authors.affiliation: UZ Leuven, Gynaecology and Obstetrics, Herestraat 49, 3000 Leuven, Belgium.
authors.forename: I
authors.initials: I
authors.lastname: Vergote
keywords: DC; Ovarian cancer; cancer; dendritic cell; immunotherapy; targeted therapy